Table 3. Recurrence-related principal components and correlated clinical factors.
| Cox proportional hazard model | |||||
| Rank | Principal components | hazard ratio | p-value | Notable correlated clinical factors | p-value |
| 1 | PC3 | 0.9592 | 0.0171 | serum, AFP* | <0.0001 |
| serum, total-bilirubin* | 0.0009 | ||||
| HBV antigen§ | 0.0020 | ||||
| 2 | PC16 | 0.9044 | 0.0207 | platelet* | 0.0040 |
| Max diameter of tumor* | 0.0135 | ||||
| T-factor (clinical)** | 0.0202 | ||||
| 3 | PC1 | 1.0335 | 0.0244 | serum, PIVKA-II* | 0.0018 |
| gender§ | 0.0398 | ||||
| 4 | PC4 | 1.0514 | 0.0246 | HCV antibody§ | 0.0002 |
| serum, AST* | 0.0037 | ||||
| platelet* | 0.0071 | ||||
| 5 | PC5 | 0.9591 | 0.0434 | capsule formation (pathological)§ | <0.0001 |
| presence of liver cirrhosis§ | 0.0042 | ||||
| ICG-R15* | 0.0198 | ||||
*: continuous variables,
**: category variables,
§: dichotonized variables.
The p-values of correlation between PCs and clinical factors were calculated by Pearson's correlation analysis, Kruskal-Wallis test, and t-test for continuous, category, and dichotonized variables, respectively.